logo Ampleia blanc



Photo de Alexandre LEMOALLE



Alexandre brings to Ampleia three decades of experience across pharma, biotech and investment banking.

Alexandre is Head of Strategic Projects at Genethon and Managing Partner at Finpact, a French boutique dedicated to fund raising in healthcare and planet care.

He was Head of Business Development and Partnerships at Genethon where we contributed to the execution of strategic deals.

Before joining Genethon, Alexandre spent 20 years at Sanofi including ten years in finance across in Europe and Asia and ten years general management and executive positions. As part of his time at Sanofi, he led the group in 25 acquisitions including Genzyme in 2011 and was CFO Asia, member of the Finance ExCom of Sanofi.

Alexandre is graduated from Institut Supérieur de Gestion (ISG) business school.

Photo de Pierre-Albert COLCOMB


chief operating officer

Pierre-Albert joined Ampleia at inception in 2023, bringing a decade of experience in biotech and finance.

Before joining Ampleia, Pierre-Albert was Business Development Director at Genethon, a leading gene therapy developer where he contributed to crafting deals with key players in rare diseases and gene therapy including Sarepta, Spark (acq. by Roche) or AveXis (acq. by Novartis). He was instrumental in the creation of several biotechs, including Atamyo Therapeutics. As part of his position, Pierre-Albert was also responsible for the business development activities of I-Stem, a research center dedicated to cell culture and differentiation. He negotiated several deals in the field of drug screening and cell therapy, including a strategic partnership with Urgo Group in skin diseases.
Pierre-Albert started his career as an analyst at Clipperton Finance, a technology-focused investment bank.

He graduated from ESPCI Paris and ESSEC Business School.

Our Partners

logo afm telethon

Created in 1958 in France, AFM-Telethon is an association of patients dedicated to supporting patients and developing treatments for rare diseases. All along its history, AFM-Telethon has taken a pioneering role financing disruptive research and creating its own laboratories to find treatments for these neglected diseases, and bring them to patients. Within 30 years of research, AFM-Telethon has invested €1.7b to design treatments and bring them to patient’s bedside. Supported by a wide and international network of scientists, developers and clinicians, the technologies initiated by AFM-Telethon are now becoming real therapeutic options for rare diseases patients and give hope to millions of patient affected by rare and non-rare indications.